{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-024996","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.179210+00:00","generated_at":"2026-05-16T16:52:23.130660+00:00","sec_items":["1.01","2.01","3.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"LIXTE acquires Liora Technologies' proton therapy platform; consideration includes stock, crypto, cash, royalty","bullets":["Consideration: 2,700 Series C Preferred shares (convertible to 2.7M common), 10.56 BTC + 300 ETH, $440K cash, and 10% royalty on net revenue up to $45M.","Liora's LiGHT proton therapy system installed at Daresbury Laboratory in UK; $300M+ invested to date.","Acquisition closed Nov 24, 2025; Liora becomes wholly owned subsidiary of LIXTE.","Series C Preferred is non-voting, convertible subject to 19.99% limit until shareholder approval at 2026 annual meeting.","CEO says LiGHT platform complements LB-100 pipeline and enables potential recurring revenue model."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-024996","json":"https://secwatch.observer/filing/0001493152-25-024996.json","markdown":"https://secwatch.observer/filing/0001493152-25-024996.md","text":"https://secwatch.observer/filing/0001493152-25-024996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/0001493152-25-024996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T16:52:23.130660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19ffa6c3b964fc7654c4fc24cdb41af927f13412","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.: Filed Certificate of Designations creating Series C Convertible Preferred Stock with 2,700 shares, $1,000 stated value, no dividends, limited voting rights, liquidation preference senior to junior securities, convertible into common stock subject to beneficial ownership limitations (effective 2025-11-24).","evidence_excerpt":"On November 24, 2025, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the “ Certificate of Designation ”) with the Secretary of State of the State of Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/0001493152-25-024996-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-11-24"}],"fact_type":"governance_change"},{"claim_id":"aa73720bdb9a8cfb5ca09a679bf5adb474121e9c","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC. completed an acquisition involving Orbit Capital Inc. for 2,700 shares of the Company's Series C Preferred Stock, $1,000 stated value per share; 10.56 Bitcoin and 300 Ethereum; $440,000 in cash; and a royalty agreement (closed 2025-11-24).","evidence_excerpt":"pursuant to a lease agreement. At the closing, the Company agreed to pay the following consideration (the “ Consideration ”) in exchange for the Shares: (i) issue to Seller 2,700 shares of the Company’s Series C Preferred Stock, $1,000 stated value per share (the “ Series C Preferred Stock ”) having such rights and preferences as set forth in the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225024996/0001493152-25-024996-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Orbit Capital Inc."},{"label":"Consideration","value":"2,700 shares of the Company's Series C Preferred Stock, $1,000 stated value per share; 10.56 Bitcoin and 300 Ethereum; $440,000 in cash; and a royalty agreement"},{"label":"Closing","value":"2025-11-24"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}